U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H16N2.ClH
Molecular Weight 248.751
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ATIPAMEZOLE HYDROCHLORIDE

SMILES

Cl.CCC1(CC2=C(C1)C=CC=C2)C3=CN=CN3

InChI

InChIKey=PCCVCJAQMHDWJY-UHFFFAOYSA-N
InChI=1S/C14H16N2.ClH/c1-2-14(13-9-15-10-16-13)7-11-5-3-4-6-12(11)8-14;/h3-6,9-10H,2,7-8H2,1H3,(H,15,16);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H16N2
Molecular Weight 212.2902
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116099.pdf https://www.zoetisus.com/products/dogs/antisedan-_atipamezole_.aspx

Atipamezole is a synthetic α2-adrenergic antagonist. It competitively inhibits α2-adrenergic receptors. Atipamezole is indicated for the reversal of the sedative and analgesic effects of Dexdomitor and Domitor in dogs. Adverse reactions: occasional vomiting may occur. At times, a period of excitement or apprehensiveness may be seen in dogs treated with atipamezole. Other effects of atipamezole include hypersalivation, diarrhea, and tremors.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Antisedan

Approved Use

It is indicated for the reversal of the clinical effects of the sedative and analgesic agents.

Launch Date

1996
PubMed

PubMed

TitleDatePubMed
Rapid reversal of alpha 2-adrenoceptor agonist effects by atipamezole in human volunteers.
1991 Feb
A comparative study of the reversal by different alpha 2-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine.
1996 Feb
Systemic administration of atipamezole, an alpha 2-antagonist, can reduce scopolamine-induced hyperactivity in rats.
1997 Oct
Alpha(2A) adrenoceptors contribute to feedback inhibition of capsaicin-induced hyperalgesia.
2004 Jul
Altered glucose homeostasis in alpha2A-adrenoceptor knockout mice.
2004 Nov 28
Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.
2005 Feb
Benzo(alpha)pyrene-induced up-regulation of CYP1A2 gene expression: role of adrenoceptor-linked signaling pathways.
2006 Jun 20
Seizures during medetomindine sedation and local anaesthesia in two dogs undergoing skin biopsy.
2009 May
Patents

Patents

Sample Use Guides

The atipamezole dose for the reversal of Dexdomitor or Domitor is 3750 ug/m2 (intravenous) or 5000 ug/m2 (intramuscular).
Route of Administration: Other
Affinity of atipamezole to a1- and a2-adrenoceptors in rat brain membranes is 13,300 and 1.6 nM respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:35:48 GMT 2023
Edited
by admin
on Fri Dec 15 17:35:48 GMT 2023
Record UNII
2W4279571X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATIPAMEZOLE HYDROCHLORIDE
GREEN BOOK   MART.   MI  
Common Name English
ATIPAMEZOLE HYDROCHLORIDE [GREEN BOOK]
Common Name English
ATIPAMEZOLE HYDROCHLORIDE [MI]
Common Name English
ATIPAMEZOLE HYDROCHLORIDE [MART.]
Common Name English
ATIPAMEZOLE HCL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29713
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
Code System Code Type Description
PUBCHEM
13649426
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY
NCI_THESAURUS
C80011
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY
DRUG BANK
DBSALT001642
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY
RXCUI
390043
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m2122
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY Merck Index
CAS
104075-48-1
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY
FDA UNII
2W4279571X
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY
SMS_ID
300000029152
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY
EPA CompTox
DTXSID2048583
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY
DAILYMED
2W4279571X
Created by admin on Fri Dec 15 17:35:49 GMT 2023 , Edited by admin on Fri Dec 15 17:35:49 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY